Caribou Biosciences

Caribou Biosciences is a clinical-stage biopharmaceutical company that is dedicated to developing transformative therapies to treat devastating human diseases. Founded in 2011 by pioneers in CRISPR genome editing, the company leverages its proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. Caribou firmly believes that cell therapies are crucial for the present and future of cancer therapy and that advanced genome editing is essential to create sophisticated cell therapies for a variety of malignancies. The company is focused on developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. In line with its mission to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing, Caribou Biosciences fosters a culture of openness and diversity. The company prides itself on encouraging the exchange of new ideas and embracing diverse perspectives, believing that teams achieve their best work when members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met. In its latest development, Caribou Biosciences secured a significant $125.00M Post-IPO Equity investment on 13 July 2023, showcasing strong support and investor confidence in the company's mission and potential. With its headquarters in the United States and a focus on the Biotechnology and Health Care industries, Caribou Biosciences continues to drive forward its innovative approach to tackling challenging diseases, particularly in the realm of cancer therapy. For those interested in being part of this groundbreaking initiative, the company's job openings can be found at Caribou Biosciences Careers.